Literature DB >> 28370285

Identification and Characterization of a Nationwide Danish Adult Common Variable Immunodeficiency Cohort.

L Westh1, T H Mogensen1,2, L S Dalgaard1, J M Bernth Jensen3, T Katzenstein4, A-B E Hansen5, O D Larsen6, S Terpling7, T L Nielsen8, C S Larsen1,2.   

Abstract

In this study, we identified all adults living in Denmark diagnosed with common variable immunodeficiency (CVID) and characterized them according to clinical presentation and EUROclass classification. Using a retrospective, cross-sectional design, possible CVID patients were identified in the Danish National Patient Register and Centers in Denmark treating patients with primary immunodeficiencies. The CVID diagnosis was verified by review of medical records. One-hundred-seventy-nine adults with CVID were identified. This corresponds to a prevalence of 1:26,000. The median age at onset of symptoms was 29 years with no sex difference. The median age at diagnosis was 40 years. Males were diagnosed earlier with a peak in the fourth decade of life, whereas females were diagnosed later with a peak in the sixth decade. The median diagnostic delay was seven years. Recurrent sinopulmonary infections were seen in 92.7% of the patients. The prevalence of non-infectious complications was similar to that of previously reported cohorts: bronchiectasis (35.8%), splenomegaly (22.4%), lymphadenopathy (26.3%), granulomatous inflammation (3.9%) and idiopathic thrombocytopenic purpura (14.5%). Non-infectious complications were strongly associated with B cell phenotype, with all having a reduced number of isotype-switched memory B cells. One-hundred-seventy (95%) were treated with immunoglobulin replacement therapy, primarily administered subcutaneously. According to international guidelines, diagnostic evaluation was inadequate in most cases. This study emphasizes the need for improved diagnostic criteria and more awareness of CVID as a differential diagnosis. Diagnosis and management of CVID patients is a challenge requiring specialists with experience in the field of PID.
© 2017 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Mesh:

Year:  2017        PMID: 28370285     DOI: 10.1111/sji.12551

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  18 in total

1.  Lymphoma as an Exclusion Criteria for CVID Diagnosis Revisited.

Authors:  Vincent Allain; Virginie Grandin; Véronique Meignin; Rémi Bertinchamp; David Boutboul; Claire Fieschi; Lionel Galicier; Laurence Gérard; Marion Malphettes; Jacinta Bustamante; Mathieu Fusaro; Nathalie Lambert; Jérémie Rosain; Christelle Lenoir; Sven Kracker; Frédéric Rieux-Laucat; Sylvain Latour; Jean-Pierre de Villartay; Capucine Picard; Eric Oksenhendler
Journal:  J Clin Immunol       Date:  2022-09-26       Impact factor: 8.542

2.  [Common variable immune deficiency in adult patients: analysis of 13 cases and literature review].

Authors:  Shenglan Gong; Yin Pu; Lingli Xie; Xiaoya Yang; Hui Mao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-08-30

3.  How to Identify Common Variable Immunodeficiency Patients Earlier: General Practice Patterns.

Authors:  Frederik V Ilkjær; Line D Rasmussen; Raquel Martin-Iguacel; Lena Westh; Terese L Katzenstein; Ann-Brit E Hansen; Thyge L Nielsen; Carsten S Larsen; Isik S Johansen
Journal:  J Clin Immunol       Date:  2019-08-01       Impact factor: 8.317

4.  Bronchiectasis is associated with delayed diagnosis and adverse outcomes in the New Zealand Common Variable Immunodeficiency Disorders cohort study.

Authors:  R Ameratunga; A Jordan; A Cavadino; S Ameratunga; T Hills; R Steele; M Hurst; B McGettigan; I Chua; M Brewerton; N Kennedy; W Koopmans; Y Ahn; R Barker; C Allan; P Storey; C Slade; A Baker; L Huang; S-T Woon
Journal:  Clin Exp Immunol       Date:  2021-04-12       Impact factor: 5.732

5.  Unexpectedly High Prevalence of Common Variable Immunodeficiency in Finland.

Authors:  Jannica S Selenius; Timi Martelius; Sampsa Pikkarainen; Sanna Siitonen; Eero Mattila; Risto Pietikäinen; Pekka Suomalainen; Arja H Aalto; Janna Saarela; Elisabet Einarsdottir; Asko Järvinen; Martti Färkkilä; Juha Kere; Mikko Seppänen
Journal:  Front Immunol       Date:  2017-09-28       Impact factor: 7.561

6.  The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data.

Authors:  Irina Odnoletkova; Gerhard Kindle; Isabella Quinti; Bodo Grimbacher; Viviane Knerr; Benjamin Gathmann; Stephan Ehl; Nizar Mahlaoui; Philippe Van Wilder; Kris Bogaerts; Esther de Vries
Journal:  Orphanet J Rare Dis       Date:  2018-11-12       Impact factor: 4.123

7.  Delayed Diagnosis and Complications of Predominantly Antibody Deficiencies in a Cohort of Australian Adults.

Authors:  Charlotte A Slade; Julian J Bosco; Tran Binh Giang; Elizabeth Kruse; Robert G Stirling; Paul U Cameron; Fiona Hore-Lacy; Michael F Sutherland; Sara L Barnes; Stephen Holdsworth; Samar Ojaimi; Gary A Unglik; Joseph De Luca; Mittal Patel; Jeremy McComish; Kymble Spriggs; Yang Tran; Priscilla Auyeung; Katherine Nicholls; Robyn E O'Hehir; Philip D Hodgkin; Jo A Douglass; Vanessa L Bryant; Menno C van Zelm
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

8.  Shorter Diagnostic Delay in Polish Adult Patients With Common Variable Immunodeficiency and Symptom Onset After 1999.

Authors:  Marcin Ziętkiewicz; Ewa Więsik-Szewczyk; Aleksandra Matyja-Bednarczyk; Katarzyna Napiórkowska-Baran; Zbigniew Zdrojewski; Karina Jahnz-Różyk
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

9.  Mild Hypogammaglobulinemia Can Be a Serious Condition.

Authors:  Lisanne M A Janssen; Paul Bassett; Thomas Macken; Jolanda van Esch; Hans Pruijt; Arnoud Knoops; Markus Sköld; Antony Parker; Jolanda de Vries; Esther de Vries
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

10.  All Patients With Common Variable Immunodeficiency Disorders (CVID) Should Be Routinely Offered Diagnostic Genetic Testing.

Authors:  Rohan Ameratunga; Klaus Lehnert; See-Tarn Woon
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.